NASDAQ:CBST - Cubist Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cubist Pharmaceuticals logoCubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive CBST News and Ratings via Email

Sign-up to receive the latest news and ratings for CBST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:CBST
CUSIP22967810
Phone+1-781-8608660

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

Cubist Pharmaceuticals (NASDAQ:CBST) Frequently Asked Questions

What is Cubist Pharmaceuticals' stock symbol?

Cubist Pharmaceuticals trades on the NASDAQ under the ticker symbol "CBST."

How were Cubist Pharmaceuticals' earnings last quarter?

Cubist Pharmaceuticals Inc (NASDAQ:CBST) announced its quarterly earnings data on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.04 by $0.54. The biopharmaceutical company earned $309.20 million during the quarter, compared to analysts' expectations of $305.50 million. The business's revenue for the quarter was up 16.2% on a year-over-year basis. During the same period last year, the company earned $0.41 earnings per share. View Cubist Pharmaceuticals' Earnings History.

Has Cubist Pharmaceuticals been receiving favorable news coverage?

Media stories about CBST stock have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cubist Pharmaceuticals earned a media and rumor sentiment score of 0.13 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.51 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Cubist Pharmaceuticals.

How do I buy shares of Cubist Pharmaceuticals?

Shares of CBST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Cubist Pharmaceuticals?

Cubist Pharmaceuticals' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.


MarketBeat Community Rating for Cubist Pharmaceuticals (NASDAQ CBST)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  419
MarketBeat's community ratings are surveys of what our community members think about Cubist Pharmaceuticals and other stocks. Vote "Outperform" if you believe CBST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.